Baird lowered the firm’s price target on Certara (CERT) to $13 from $18 and keeps a Neutral rating on the shares. The firm views recent CRO reports noting downward adjustments in pharma spending toward the end of 3Q24 as increasing risks that Certara sees more muted 4Q24 seasonality and FY25 improvement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT: